High glucose concentrations induce TNF-α production through the down-regulation of CD33 in primary human monocytes

BMC Immunology

Volumn 13, Issue , 2012, Pages

  Gonzalez, Yolanda ^a   Herrera, M Teresa ^a   Soldevila, Gloria ^b   Garcia Garcia, Lourdes ^c   Fabián, Guadalupe ^a   Pérez Armendariz, E Martha ^b   Bobadilla, Karen ^a   Guzmán Beltrán, Silvia ^a   Sada, Eduardo ^a   Torres, Martha ^a  

^a INSTITUTO NACIONAL DE ENFERMEDADES RESPIRATORIAS   (Mexico)

^b UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

^c INSTITUTO NACIONAL DE SALUD PÚBLICA   (Mexico)

Author keywords

Antioxidant; Cytokines; Monocytes; ROS; Siaglec 3; Type 2 diabetes

Indexed keywords

ALPHA TOCOPHEROL; CD33 ANTIGEN; INTERLEUKIN 12P70; INTERLEUKIN 8; MESSENGER RNA; REACTIVE OXYGEN METABOLITE; SUPPRESSOR OF CYTOKINE SIGNALING 3; TUMOR NECROSIS FACTOR ALPHA; ANTIOXIDANT; AUTACOID; CYTOKINE; DIFFERENTIATION ANTIGEN; GLUCOSE; LEUKOCYTE ANTIGEN; SOCS3 PROTEIN, HUMAN; SUPPRESSOR OF CYTOKINE SIGNALING;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; HYPERGLYCEMIA; MALE; MONOCYTE; NON INSULIN DEPENDENT DIABETES MELLITUS; PROTEIN EXPRESSION; RECEPTOR DOWN REGULATION; BIOSYNTHESIS; BLOOD; DOWN REGULATION; DRUG EFFECT; GENE EXPRESSION REGULATION; GENETICS; IMMUNOLOGY; METABOLISM; MIDDLE AGED;

ADULT; ALPHA-TOCOPHEROL; ANTIGENS, CD; ANTIGENS, DIFFERENTIATION, MYELOMONOCYTIC; ANTIOXIDANTS; CYTOKINES; DIABETES MELLITUS, TYPE 2; DOWN-REGULATION; FEMALE; GENE EXPRESSION REGULATION; GLUCOSE; HUMANS; INFLAMMATION MEDIATORS; MALE; MIDDLE AGED; MONOCYTES; SUPPRESSOR OF CYTOKINE SIGNALING PROTEINS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84859724629     PISSN: None     EISSN: 14712172     Source Type: Journal    
DOI: 10.1186/1471-2172-13-19     Document Type: Article

References (44)

1. Esposito K, Nappo F, Marfella R, Giugliano G, Giugliano F, Ciotola M, Quagliaro L, Ceriello A, Giugliano D. Inflammatory cytokine concentrations are acutely increased by hyperglycemia in humans: role of oxidative stress. Circulation 2002, 106:2067-2072. 10.1161/01.CIR.0000034509.14906.AE, 12379575.
2. Temelkova-Kurktschiev T, Henkel E, Koehler C, Karrei K, Hanefeld M. Subclinical inflammation in newly detected Type II diabetes and impaired glucose tolerance. Diabetologia 2002, 45:151. 10.1007/s125-002-8256-1, 11845235.
3. Morohoshi M, Fujisawa K, Uchimura I, Numano F. Glucose-dependent interleukin 6 and tumor necrosis factor production by human peripheral blood monocytes in vitro. Diabetes 1996, 45:954-959. 10.2337/diabetes.45.7.954, 8666148.
4. Stentz FB, Umpierrez GE, Cuervo R, Kitabchi AE. Proinflammatory cytokines, markers of cardiovascular risks, oxidative stress, and lipid peroxidation in patients with hyperglycemic crises. Diabetes 2004, 53:2079-2086. 10.2337/diabetes.53.8.2079, 15277389.
5. Duncan BB, Schmidt MI, Pankow JS, Ballantyne CM, Couper D, Vigo A, Hoogeveen R, Folsom AR, Heiss G. Low-grade systemic inflammation and the development of type 2 diabetes: the atherosclerosis risk in communities study. Diabetes 2003, 52:1799-1805. 10.2337/diabetes.52.7.1799, 12829649.
6. Devaraj S, Jialal I. Increased secretion of IP-10 from monocytes under hyperglycemia is via the TLR2 and TLR4 pathway. Cytokine 2009, 47:6-10. 10.1016/j.cyto.2009.02.004, 2771557, 19447045.
7. Satoh N, Shimatsu A, Himeno A, Sasaki Y, Yamakage H, Yamada K, Suganami T, Ogawa Y. Unbalanced M1/M2 phenotype of peripheral blood monocytes in obese diabetic patients: effect of pioglitazone. Diabetes Care 2010, 33:e7. 10.2337/dc09-1315, 20040670.
8. Gacka M, Dobosz T, Szymaniec S, Bednarska-Chabowska D, Adamiec R, Sadakierska-Chudy A. Proinflammatory and atherogenic activity of monocytes in type 2 diabetes. J Diabetes Complications 2010, 24:1-8. 10.1016/j.jdiacomp.2008.07.001, 18835531.
9. Giulietti A, van Etten E, Overbergh L, Stoffels K, Bouillon R, Mathieu C. Monocytes from type 2 diabetic patients have a pro-inflammatory profile. 1,25-Dihydroxyvitamin D(3) works as anti-inflammatory. Diabetes Res ClinPract 2007, 77:47-57.
10. Demircan N, Safran BG, Soylu M, Ozcan AA, Sizmaz S. Determination of vitreous interleukin-1 (IL-1) and tumour necrosis factor (TNF) levels in proliferative diabetic retinopathy. Eye (Lond) 2006, 20:1366-1369.
11. Devaraj S, Cheung AT, Jialal I, Griffen SC, Nguyen D, Glaser N, Aoki T. Evidence of increased inflammation and microcirculatory abnormalities in patients with type 1 diabetes and their role in microvascular complications. Diabetes 2007, 56:2790-2796. 10.2337/db07-0784, 2692935, 17686944.
12. Pickup JC. Inflammation and activated innate immunity in the pathogenesis of type 2 diabetes. Diabetes Care 2004, 27:813-823. 10.2337/diacare.27.3.813, 14988310.
13. Iwata H, Soga Y, Meguro M, Yoshizawa S, Okada Y, Iwamoto Y, Yamashita A, Takashiba S, Nishimura F. High glucose up-regulates lipopolysaccharide-stimulated inflammatory cytokine production via c-jun N-terminal kinase in the monocytic cell line THP-1. J Endotoxin Res 2007, 13:227-234. 10.1177/0968051907082608, 17956941.
14. Wuensch T, Thilo F, Krueger K, Scholze A, Ristow M, Tepel M. High glucose-induced oxidative stress increases transient receptor potential channel expression in human monocytes. Diabetes 2010, 59:844-849. 10.2337/db09-1100, 2844832, 20068131.
15. Shanmugam N, Reddy MA, Guha M, Natarajan R. High glucose-induced expression of proinflammatory cytokine and chemokine genes in monocytic cells. Diabetes 2003, 52:1256-1264. 10.2337/diabetes.52.5.1256, 12716761.
16. Morohoshi M, Fujisawa K, Uchimura I, Numano F. The effect of glucose and advanced glycosylation end products on IL-6 production by human monocytes. Ann N Y AcadSci 1995, 748:562-570.
17. Ichikawa K, Yoshinari M, Iwase M, Wakisaka M, Doi Y, Iino K, Yamamoto M, Fujishima M. Advanced glycosylation end products induced tissue factor expression in human monocyte-like U937 cells and increased tissue factor expression in monocytes from diabetic patients. Atherosclerosis 1998, 136:281-287. 10.1016/S0021-9150(97)00221-9, 9543099.
18. Nishikawa T, Edelstein D, Du XL, Yamagishi S, Matsumura T, Kaneda Y, Yorek MA, Beebe D, Oates PJ, Hammes HP, et al. Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage. Nature 2000, 404:787-790. 10.1038/35008121, 10783895.
19. Orie NN, Zidek W, Tepel M. Increased intracellular generation of reactive oxygen species in mononuclear leukocytes from patients with diabetes mellitus type 2. Exp Clin Endocrinol Diabetes 2000, 108:175-180. 10.1055/s-2000-7740, 10926312.
20. Devaraj S, Venugopal SK, Singh U, Jialal I. Hyperglycemia induces monocytic release of interleukin-6 via induction of protein kinase c-{alpha} and -{beta}. Diabetes 2005, 54:85-91. 10.2337/diabetes.54.1.85, 15616014.
21. Nakamura Y, Noma M, Kidokoro M, Kobayashi N, Takei M, Kurashima S, Mukaiyama T, Kato S. Expression of CD33 antigen on normal human activated T lymphocytes. Blood 1994, 83:1442-1443.
22. Crocker PR. Siglecs in innate immunity. Curr Opin Pharmacol 2005, 5:431-437. 10.1016/j.coph.2005.03.003, 15955740.
23. Munday J, Floyd H, Crocker PR. Sialic acid binding receptors (siglecs) expressed by macrophages. J Leukoc Biol 1999, 66:705-711.
24. Cao H, Crocker PR. Evolution of CD33-related siglecs: regulating host immune functions and escaping pathogen exploitation?. Immunology 2011, 132:18-26. 10.1111/j.1365-2567.2010.03368.x, 3015071, 21070233.
25. Avril T, Attrill H, Zhang J, Raper A, Crocker PR. Negative regulation of leucocyte functions by CD33-related siglecs. Biochem Soc Trans 2006, 34:1024-1027. 10.1042/BST0341024, 17073742.
26. Orr SJ, Morgan NM, Elliott J, Burrows JF, Scott CJ, McVicar DW, Johnston JA. CD33 responses are blocked by SOCS3 through accelerated proteasomal-mediated turnover. Blood 2007, 109:1061-1068.
27. Lajaunias F, Dayer JM, Chizzolini C. Constitutive repressor activity of CD33 on human monocytes requires sialic acid recognition and phosphoinositide 3-kinase-mediated intracellular signaling. Eur J Immunol 2005, 35:243-251. 10.1002/eji.200425273, 15597323.
28. Shamsasenjan K, Otsuyama K, Abroun S, Iqbal MS, Mahmoud MS, Asaoku H, Kawano MM. IL-6-induced activation of MYC is responsible for the down-regulation of CD33 expression in CD33+ myeloma cells. Int J Hematol 2009, 89:310-318. 10.1007/s12185-009-0256-y, 19259613.
29. Wu JH, Ward NC, Indrawan AP, Almeida CA, Hodgson JM, Proudfoot JM, Puddey IB, Croft KD. Effects of alpha-tocopherol and mixed tocopherol supplementation on markers of oxidative stress and inflammation in type 2 diabetes. Clin Chem 2007, 53:511-519. 10.1373/clinchem.2006.076992, 17272491.
30. Muller T, Grandbarbe L, Morga E, Heuschling P, Luu B. Tocopherol long chain fatty alcohols decrease the production of TNF-alpha and NO radicals by activated microglial cells. Bioorg Med Chem Lett 2004, 14:6023-6026. 10.1016/j.bmcl.2004.09.078, 15546721.
31. Deopurkar R, Ghanim H, Friedman J, Abuaysheh S, Sia CL, Mohanty P, Viswanathan P, Chaudhuri A, Dandona P. Differential effects of cream, glucose, and orange juice on inflammation, endotoxin, and the expression of Toll-like receptor-4 and suppressor of cytokine signaling-3. Diabetes Care 2010, 33:991-997. 10.2337/dc09-1630, 2858203, 20067961.
32. Ghanim H, Sia CL, Upadhyay M, Korzeniewski K, Viswanathan P, Abuaysheh S, Mohanty P, Dandona P. Orange juice neutralizes the proinflammatory effect of a high-fat, high-carbohydrate meal and prevents endotoxin increase and Toll-like receptor expression. Am J Clin Nutr 2010, 91:940-949. 10.3945/ajcn.2009.28584, 2844681, 20200256.
33. Lee JH, Lee W, Kwon OH, Kim JH, Kwon OW, Kim KH, Lim JB. Cytokine profile of peripheral blood in type 2 diabetes mellitus patients with diabetic retinopathy. Ann Clin Lab Sci 2008, 38:361-367.
34. Dasu MR, Devaraj S, Jialal I. High glucose induces IL-1beta expression in human monocytes: mechanistic insights. Am J Physiol Endocrinol Metab 2007, 293:E337-E346. 10.1152/ajpendo.00718.2006, 2676171, 17426109.
35. Hill JR, Kwon G, Marshall CA, McDaniel ML. Hyperglycemic levels of glucose inhibit interleukin 1 release from RAW 264.7 murine macrophages by activation of protein kinase C. J Biol Chem 1998, 273:3308-3313. 10.1074/jbc.273.6.3308, 9452447.
36. Otto NM, Schindler R, Lun A, Boenisch O, Frei U, Oppert M. Hyperosmotic stress enhances cytokine production and decreases phagocytosis in vitro. Crit Care 2008, 12:R107. 10.1186/cc6989, 2575596, 18710523.
37. Hancu N, Netea MG, Baciu I. High glucose concentrations increase the tumor necrosis factor-alpha production capacity by human peripheral blood mononuclear cells. Rom J Physiol 1998, 35:325-330.
38. Corrales JJ, Almeida M, Burgo RM, Hernandez P, Miralles JM, Orfao A. Decreased production of inflammatory cytokines by circulating monocytes and dendritic cells in type 2 diabetic men with atherosclerotic complications. J Diabetes Complications 2007, 21:41-49. 10.1016/j.jdiacomp.2005.09.006, 17189873.
39. Ghanim H, Abuaysheh S, Sia CL, Korzeniewski K, Chaudhuri A, Fernandez-Real JM, Dandona P. Increase in plasma endotoxin concentrations and the expression of Toll-like receptors and suppressor of cytokine signaling-3 in mononuclear cells after a high-fat, high-carbohydrate meal: implications for insulin resistance. Diabetes Care 2009, 32:2281-2287. 10.2337/dc09-0979, 2782991, 19755625.
40. Emanuelli B, Peraldi P, Filloux C, Chavey C, Freidinger K, Hilton DJ, Hotamisligil GS, Van Obberghen E. SOCS-3 inhibits insulin signaling and is up-regulated in response to tumor necrosis factor-alpha in the adipose tissue of obese mice. J Biol Chem 2001, 276:47944-47949.
41. Ehlting C, Lai WS, Schaper F, Brenndorfer ED, Matthes RJ, Heinrich PC, Ludwig S, Blackshear PJ, Gaestel M, Haussinger D, Bode JG. Regulation of suppressor of cytokine signaling 3 (SOCS3) mRNA stability by TNF-alpha involves activation of the MKK6/p38MAPK/MK2 cascade. J Immunol 2007, 178:2813-2826.
42. American Diabetes A Diagnosis and classification of diabetes mellitus. Diabetes Care 2011, 34:S62-S69. Suppl 1, 3006051, 21193628, American Diabetes A.
43. Boyum A. Isolation of lymphocytes, granulocytes and macrophages. Scand J Immunol 1976, Suppl 5:9-15.
44. Denizot F, Lang R. Rapid colorimetric assay for cell growth and survival. Modifications to the tetrazolium dye procedure giving improved sensitivity and reliability. J Immunol Methods 1986, 89:271-277. 10.1016/0022-1759(86)90368-6, 3486233.